Drug Profile

RTX 001 - Resolution Therapeutics

Alternative Names: RTX-001 - Resolution Therapeutics

Latest Information Update: 17 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Resolution Therapeutics
Class Anti-inflammatories; Antifibrotics; Cell therapies; Gene therapies
Mechanism of Action Macrophage replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Liver cirrhosis

Most Recent Events

11 Sep 2026 Resolution Therapeutics completes enrolment in the EMERALD trial for Liver cirrhosis in United Kingdom and Spain (NCT06823713)
01 Sep 2026 Resolution Therapeutics plans pre-IND meeting with US FDA for RTX 001
01 Sep 2026 Resolution Therapeutics plans a pivotal clinical trial for Liver cirrhosis (Late-stage diseases) (IV) in 2027

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com